Does substance use disorder affect clinical expression in first-hospitalization patients with schizophrenia? Analysis of a prospective cohort

Psychiatry Research

Volumn 210, Issue 3, 2013, Pages 780-786

  Picci, Rocco Luigi ^a   Versino, Elisabetta ^a   Oliva, Francesco ^a   Giaretto, Roberta Margherita ^a   Ostacoli, Luca ^a   Trivelli, Federica ^a   Venturello, Sara ^b   Furlan, Pier Maria ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b ASL TO2   (Italy)

Author keywords

Drug use disorder; Hospitalization; Length of stay; Psychopathology; Psychotic disorders; Substance abuse; Substance induced psychoses

Indexed keywords

AMPHETAMINE; CARBAMAZEPINE; HALOPERIDOL; LYSERGIDE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; VALPROIC ACID;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CANNABIS ADDICTION; COCAINE DEPENDENCE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORIENTATION; DRUG DEPENDENCE; FEMALE; HEROIN DEPENDENCE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE; THOUGHT DISORDER; HOSPITAL ADMISSION; MIDDLE AGED; PSYCHOLOGY; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT ADMISSION; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84888292878     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.08.043     Document Type: Article

References (66)

1. Addington J., Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatrica Scandinavica 2007, 115:304-309.
2. Allebeck P., Adamsson C., Engström A., Rydberg U. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatrica Scandinavica 1993, 88:21-24.
3. Andersen J., Larsen J.K., Schultz V., Nielsen B.M., Kørner A., Behnke K., Munk-Andersen E., Butler B., Allerup P., Bech P. The Brief Psychiatric Rating Scale. Dimension of schizophrenia-reliability and construct validity. Psychopathology 1989, 22:168-176.
4. Archie S., Rush B.R., Akhtar-Danesh N., Norman R., Malla A., Roy P., Zipursky R.B. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophrenia Bulletin 2007, 33:1354-1363.
5. Averill P.M., Hopko D.R., Small D.R., Greenlee H.B., Varner R.V. The role of psychometric data in predicting inpatient mental health service utilization. Psychiatric Quarterly 2001, 72:215-235.
6. Barnett J.H., Werners U., Secher S.M., Hill K.E., Brazil R., Masson K., Pernet D.E., Kirkbride J.B., Murray G.K., Bullmore E.T., Jones P.B. Substance use in a population-based clinic sample of people with first-episode psychosis. The British Journal of Psychiatry 2007, 190:515-520.
7. Barrigón M.L., Gurpegui M., Ruiz-Veguilla M., Diaz F.J., Anguita M., Sarramea F., Cervilla J. Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. Journal of Psychiatric Research 2010, 44:413-420.
8. Bartels S.J., Teague G.B., Drake R.E., Clark R.E., Bush P.W., Noordsy D.L. Substance abuse in schizophrenia: service utilization and costs. The Journal of Nervous and Mental Disease 1993, 181:227-232.
9. Bersani G., Orlandi V., Kotzalidis G.D., Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. European Archives of Psychiatry and Clinical Neuroscience 2002, 252:86-92.
10. Bühler B., Hambrecht M., Löffler W., an der Heiden W., Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophrenia Research 2002, 54:243-251.
11. Cantor-Graae E., Nordström L.G., McNeil T.F. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophrenia Research 2001, 48:69-82.
12. Cantwell R., Brewin J., Glazebrook C., Dalkin T., Fox R., Medley I., Harrison G. Prevalence of substance misuse in first-episode psychosis. The British Journal of Psychiatry 1999, 174:150-153.
13. Carey K.B., Maisto S.A., Carey M.P., Purnine D.M. Measuring readiness-to-change substance misuse among psychiatric outpatients I. Reliability and validity of self-report measures. Journal of Studies on Alcohol 2001, 62:79-88.
14. Caton C.L.M., Hasin D.S., Shrout P.E., Drake R.E., Dominguez B., First M.B., Samet S., Schanzer B. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. The British Journal of Psychiatry 2007, 190:105-111.
15. Chang G., Brenner L., Bryant K. Factors predicting inpatient length of stay in a CMHC. Hospital and Community Psychiatry 1991, 42:853-855.
16. Compton M.T., Broussard B., Ramsay C.E., Stewart T. Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis. Schizophrenia Research 2011, 126:71-76.
17. Compton M.T., Furman A.C., Kaslow N.J. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophrenia Research 2004, 71:61-64.
18. Compton M.T., Kelley M.E., Ramsay C.E., Pringle M., Goulding S.M., Esterberg M.L., Stewart T., Walker E.F. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. The American Journal of Psychiatry 2009, 166:1251-1257.
19. Dalmau A., Bergman B., Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness?. European Psychiatry 1999, 14:366-371.
20. Dawe S., Geppert L., Occhipinti S., Kingswell W. A comparison of the symptoms and short-term clinical course in inpatients with substance-induced psychosis and primary psychosis. Journal of Substance Abuse Treatment 2011, 40:95-101.
21. de Haan L., van Amelsvoort T., Dingemans P., Linszen D. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry 2007, 40:264-268.
22. Dubertret C., Bidard I., Adès J., Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophrenia Research 2006, 86:284-290.
23. Farrelly S., Harris M.G., Henry L.P., Purcell R., Prosser A., Schwartz O., Jackson H., McGorry P.D. Prevalence and correlates of comorbidity 8 years after a first psychotic episode. Acta Psychiatrica Scandinavica 2007, 116:62-70.
24. First M.B. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version 1997, American Psychiatric Press, Washington DC.
25. Fowler I.L., Carr V.J., Carter N.T., Lewin T.J. Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin 1998, 24:443-455.
26. Gearon J.S., Bellack A.S. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients. Schizophrenia Research 2000, 43:65-70.
27. Hambrecht M., Häfner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry 1996, 40:1155-1163.
28. Hambrecht M., Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. The Australian and New Zealand Journal of Psychiatry 2000, 34:468-475.
29. Hedlund J., Wieweg B. The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. Journal of Operational Psychiatry 1980, 11:48-65.
30. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.-U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ: British Medical Journal 2005, 330:11.
31. Herr B.E., Abraham H.D., Anderson W. Length of stay in a general hospital psychiatric unit. General Hospital Psychiatry 1991, 13:68-70.
32. Huntley D.A., Cho D.W., Christman J., Csernansky J.G. Predicting length of stay in an acute psychiatric hospital. Psychiatric Services 1998, 49:1049-1053.
33. Katz G., Durst R., Shufman E., Bar-Hamburger R., Grunhaus L. Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients. Comprehensive Psychiatry 2010, 51:37-41.
34. Kavanagh D.J., Waghorn G., Jenner L., Chant D.C., Carr V., Evans M., Hemnan H., Jablensky A., McGrath J.J. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research 2004, 66:115-124.
35. Kendler K.S., Gallagher T.J., Abelson J.M., Kessler R.C. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Archives of General Psychiatry 1996, 53:1022-1031.
36. Kessler R.C., Birnbaum H., Demler O., Falloon I.R.H., Gagnon E., Guyer M., Howes M.J., Kendler K.S., Shi L., Walters E., Wu E.Q. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biological Psychiatry 2005, 58:668-676.
37. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1994, 51:8-19.
38. Koskinen J., Löhönen J., Koponen H., Isohanni M., Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 2010, 36:1115-1130.
39. Lachar D., Bailley S.E., Rhoades H.M., Espadas A., Aponte M., Cowan K.A., Gummattira P., Kopecky C.R., Wassef A. New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. Psychological assessment 2001, 13:384-395.
40. Lambert M., Conus P., Lubman D.I., Wade D., Yuen H., Moritz S., Naber D., McGorry P.D., Schimmelmann B.G. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica 2005, 112:141-148.
41. Larsen T.K., Melle I., Auestad B., Friis S., Haahr U., Johannessen J.O., Opjordsmoen S., Rund B.R., Simonsen E., Vaglum P., McGlashan T.H. Substance abuse in first-episode non-affective psychosis. Schizophrenia Research 2006, 88:55-62.
42. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 1994, 51:273-279.
43. Lykke J., Hesse M., Austin S.F., Oestrich I. Validity of the BPRS, the BDI and the BAI in dual diagnosis patients. Addictive Behaviors 2008, 33:292-300.
44. Margolese H.C., Carlos Negrete J., Tempier R., Gill K. A 12-month prospective follow-up study of patients with schizophrenia-spectrum disorders and substance abuse: changes in psychiatric symptoms and substance use. Schizophrenia Research 2006, 83:65-75.
45. Marshall, M., Rathbone, J., 2011. Early intervention for psychosis. Cochrane database of systematic reviews (Online), CD004718.
46. Mauri M.C., Volonteri L.S., De Gaspari I.F., Colasanti A., Brambilla M.A., Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clinical Practice and Epidemiology in Mental Health 2006, 2:4.
47. Mazzoncini R., Donoghue K., Hart J., Morgan C., Doody G.A., Dazzan P., Jones P.B., Morgan K., Murray R.M., Fearon P. Illicit substance use and its correlates in first episode psychosis. Acta Psychiatrica Scandinavica 2010, 121:351-358.
48. Mc Lellan A.T., Woody G.E., O'Brien C.P. Development of psychiatric illness in drug abusers. Possible role of drug preference. The New England Journal of Medicine 1979, 301:1310-1314.
49. Modestin J., Gladen C.J., Christen S. A comparative study on schizophrenic patients with dual diagnosis. Journal of Addictive Diseases 2001, 20:41-51.
50. Mortimer A.M. Symptom rating scales and outcome in schizophrenia. The British Journal of Psychiatry 2007, Suppl. 50:s7-14.
51. Mueser K.T., Curran P.J., McHugo G.J. Factor structure of the Brief Psychiatric Rating Scale in schizophrenia. Psychological Assessment 1997, 9(3):196-204.
52. Overall J.E., Gorham D.R. The Brief Psychiatric Rating Scale. Psychological Reports 1962, 10:799-812.
53. Rabinowitz J., Bromet E.J., Lavelle J., Carlson G., Kovasznay B., Schwartz J.E. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine 1998, 28:1411-1419.
54. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA: The Journal of the American Medical Association 1990, 264:2511-2518.
55. Rosenbaum B., Valbak K., Harder S., Knudsen P., Køster A., Lajer M., Lindhardt A., Winther G., Petersen L., Jørgensen P., Nordentoft M., Andreasen A.H. The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis. The British Journal of Psychiatry 2005, 186:394-399.
56. Schafer A. Meta-analysis of the brief psychiatric rating scale factor structure. Psychological Assessment 2005, 17(3):324-335.
57. Schimmelmann B.G., Conus P., Cotton S., Kupferschmid S., McGorry P.D., Lambert M. Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. European Psychiatry 2012, 27(6):463-469.
58. Segal D.L., Hersen M., Van Hasselt V.B. Reliability of the Structured Clinical Interview for DSM-III-R: an evaluative review. Comprehensive Psychiatry 1994, 35:316-327.
59. Sevy S., Robinson D.G., Napolitano B., Patel R.C., Gunduz-Bruce H., Miller R., McCormack J., Lorell B.S., Kane J. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophrenia Research 2010, 120:101-107.
60. Skre I., Onstad S., Torgersen S., Kringlen E. High interrater reliability for the Structured Clinical Interview for DSM-III-R Axis I (SCID-I). Acta Psychiatrica Scandinavica 1991, 84:167-173.
61. Soyka M., Albus M., Immler B., Kathmann N., Hippius H. Psychopathology in dual diagnosis and non-addicted schizophrenics-are there differences?. European Archives of Psychiatry and Clinical Neuroscience 2001, 251:232-238.
62. Veen N.D., Selten J.-P., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. The American Journal of Psychiatry 2004, 161:501-506.
63. Wade D., Harrigan S., Edwards J., Burgess P.M., Whelan G., McGorry P.D. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. The British Journal of Psychiatry 2006, 189:229-234.
64. Wade D., Harrigan S., Harris M.G., Edwards J., McGorry P.D. Pattern and correlates of inpatient admission during the initial acute phase of first-episode psychosis. The Australian and New Zealand Journal of Psychiatry 2006, 40:429-436.
65. Wobrock T., Sittinger H., Behrendt B., D'Amelio R., Falkai P., Caspari D. Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2007, 257:203-210.
66. Zammit S., Moore T.H.M., Lingford-Hughes A., Barnes T.R.E., Jones P.B., Burke M., Lewis G. Effects of cannabis use on outcomes of psychotic disorders: systematic review. The British Journal of Psychiatry 2008, 193:357-363.